Now is the Right Time for Domestic Production | Hycells Achieves Full-Chain Localization, Breaking Through on Both Cost and Quality
Release Date:
2025-04-08 15:06
Recently, the U.S. government announced additional hefty tariffs on a range of Chinese goods, including biotechnology products, with tariff rates for some categories rising to over 54%. This move underscores the urgent need for greater supply-chain self-reliance and controllability. The latest U.S. tariff policy imposes substantially higher duties on critical items such as biological raw materials, culture media, and enzyme preparations, placing domestic firms that rely on imports under dual pressure: rising procurement costs and supply-chain instability—both of which are severely hampering downstream R&D and production schedules.
Shanghai Hycells Biotechnology is a biotech innovation company specializing in primary immune cell research, dedicated to providing customers with comprehensive, one-stop solutions for immune cells and stem cells. We offer compliant, ethically sound immune cell and stem cell collection services, while also introducing the high-quality, safe, and reliable HiXpan. Registered trademark A series of serum-free culture kits that deliver high quality to advance cell research and clinical applications across the industry.
U.S. tariff pressures are driving a critical push for domestic innovation and breakthroughs. Hycells Bio’s end-to-end localized solutions enable simultaneous gains in cost efficiency and product quality, accelerating the strategic shift of import substitution from a “backup option” to an “essential choice.” Hycells HiXpan ® We have achieved domestic production across the entire value chain for culture-based products, from biological raw materials to finished goods, leveraging the domestic supply chain to build a complete industrial ecosystem. Adhering rigorously to ISO standards in raw material selection, manufacturing management, and quality control, our products offer exceptional cost-performance and represent an ideal choice for import substitution.
◀
HiXpan Registered trademark Cultivation-type products
▶
HiXpan Registered trademark NK Serum-Free Culture Kit (Cytokine-Based)
A highly efficient NK cell induction and expansion kit for samples derived from human peripheral blood or umbilical cord blood.
Product Advantages
Strong expansion capacity: cells can be expanded up to 200-fold, with a post-expansion viability of ≥90%.
NK cells exhibit high purity and potent cytotoxic activity.
Suitable for fresh or cryopreserved PBMCs and CBMCs.
Chemical composition limited, safe, stable, and efficient
No antibody coating required; simple and convenient operation.
HiXpan ® NK Serum-Free Culture Kit (Trophoblast Method)
An independently developed, domestically produced original research system;
Suitable for the culture of NK cells from multiple sources, such as peripheral blood and umbilical cord blood;
High expansion fold: after 13 days of culture, NK cell expansion reaches 300–400-fold.
The effector cells exhibit high purity, with the expanded NK cell population achieving a purity of up to 90%.
Compatible with mainstream basal immune cell culture media;
Simple operation; no need to add activation or amplification reagents a second time.
When combined with Hycells’s pre-screening and cryopreservation of PBMCs, it can deliver more stable and reproducible expansion results.
HiXpan ® Serum-Free γδ T Cell Culture Kit
Product Advantages
A pure factor-induced protocol for the targeted expansion of Vδ2 cells, achieving 200–300-fold expansion, with process scalability.
Suitable for fresh/frozen PBMC
Amplification purity exceeds 90%, with high cytotoxic activity and robust expression of CD56, NKG2D, and HLA-DR.
Cells expanded ex vivo retain the capacity for sustained expansion in vivo.
HiXpan ® MSC Serum-Free Culture Kit
HiXpan Registered trademark The MSC Serum-Free Culture Kit is a high-quality, complete culture system specifically designed for the primary isolation and serial passaging of human mesenchymal stem cells under serum-free, xeno-free conditions. This kit supports primary isolation and culture of MSCs using methods such as explant culture and enzymatic digestion, enabling long-term, multi-passage cultivation while effectively preserving cell characteristics and maintaining balanced lineage differentiation potential—such as the ability to differentiate into osteoblasts, chondrocytes, and adipocytes.
Product Advantages
Serum-free and free of xenogenic animal-derived components
Mesenchymal stem cells derived from multiple tissue sources, such as umbilical cord MSCs, bone marrow MSCs, and adipose-derived MSCs.
Faster proliferation capacity, stable passage for more than 20 generations, and better maintenance of cellular differentiation potential.
Use directly—no additional components required, and no coating of the microplate is necessary.
The cells are small in size, and 20 million cells can be harvested within 72 hours of T175 culture.
HiXpan ® Serum-free cell cryopreservation solution
This cryopreservation solution is ideally suited for temperature-sensitive cell types, including routine samples, primary NK cells, γδ T cells, T cells, dendritic cells (DCs), and peripheral blood mononuclear cells (PBMCs), delivering outstanding cryopreservation performance that has been rigorously validated to outperform well-known imported brands.
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board